论文部分内容阅读
本文从经济学角度探讨我院在《北京市公费医疗、劳保医疗用药报销范围》实施前后抗感染药物的消费金额、消费数量、增长情况、消费趋势等。《报销范围》的实施对抗感染药物的影响较小,由于医师选用价廉而疗效相似的药品,使药费收入得到控制,药品使用更加规范化,做到总量控制和宏观调控。今后若干年内,大环内酯类和喹诺酮类新药的开发将成为热点,抗感染药物消费趋势将朝着高效、安全、经济的方向发展。
This article explores the consumption amount, consumption amount, growth and consumption trend of anti-infective drugs in our hospital before and after the implementation of “Beijing’s public expense medical care and medical insurance reimbursement range” from an economic perspective. The implementation of “reimbursement scope” has less impact on the anti-infective drugs. Because physicians choose cheaper and more similar drugs, the revenue from drugs is controlled and the use of medicines is more standardized and the total quantity control and macro control are achieved. In the next few years, the development of new macrolides and quinolones will become hot spots, and the trend of consumption of anti-infective drugs will move toward an efficient, safe and economical way.